Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday

Fractyl Health (NASDAQ:GUTS) is expected to be issuing its Q4 2025 resultson Monday, April 6th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, March 24th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.34. On average, analysts expect Fractyl Health to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fractyl Health Stock Performance

GUTS opened at $0.45 on Monday. The firm has a market capitalization of $71.17 million, a PE ratio of -0.24 and a beta of 1.51. Fractyl Health has a twelve month low of $0.38 and a twelve month high of $3.03. The firm’s 50-day moving average price is $0.71 and its 200 day moving average price is $1.28. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 3.23.

More Fractyl Health News

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (notably FY2026–FY2030) and trimmed near‑term loss estimates while keeping a “Buy” rating and an $8.00 price target — this signals the analyst expects meaningful recovery and eventual profitability, supporting upside versus the current sub‑$1 trade. HC Wainwright analyst note (MarketBeat)
• Positive Sentiment: Canaccord Genuity reaffirmed a “Buy” rating and an $8.00 price target, echoing the bullish analyst narrative and providing additional third‑party validation of the longer‑term thesis. Canaccord reaffirmation (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call transcript is available — the company recently reported an EPS beat for Q4 (reported EPS vs. consensus), which is supportive but investors will focus on follow‑up cadence, cash runway, and clinical/regulatory catalysts. Q4 2025 earnings call transcript (MSN)
• Negative Sentiment: TipRanks flagged “significant compliance risks” under global anti‑corruption and sanctions laws after a new risk disclosure — legal/compliance issues can slow partnerships, delay commercial progress, or increase remediation costs, creating downside risk and adding near‑term uncertainty. Compliance risk disclosure (TipRanks)

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Morgan Stanley downgraded shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Fractyl Health presently has a consensus rating of “Hold” and a consensus target price of $5.40.

Hedge Funds Weigh In On Fractyl Health

A number of institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of Fractyl Health in the 2nd quarter valued at approximately $31,000. Scientech Research LLC purchased a new stake in shares of Fractyl Health during the 3rd quarter valued at approximately $49,000. Prelude Capital Management LLC purchased a new stake in shares of Fractyl Health during the 3rd quarter valued at approximately $55,000. Jump Financial LLC acquired a new position in Fractyl Health in the fourth quarter valued at approximately $57,000. Finally, Centiva Capital LP purchased a new position in Fractyl Health in the third quarter worth approximately $78,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.